Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0007693
UniProt IDP26368
Primary gene name(s)U2AF2
Synonym gene name(s)U2AF65
Protein nameSplicing factor U2AF 65 kDa subunit
Protein functionNecessary for the splicing of pre-mRNA. By recruiting PRPF19 and the PRP19C/Prp19 complex/NTC/Nineteen complex to the RNA polymerase II C-terminal domain, CTD, and thereby pre-mRNA, may couple transcription to splicing, PubMed:21536736. Induces cardiac troponin-T, TNNT2 pre-mRNA exon inclusion in muscle. Regulates the TNNT2 exon 5 inclusion through competition with MBNL1. Binds preferentially to a single-stranded structure within the polypyrimidine tract of TNNT2 intron 4 during spliceosome assembly. Required for the export of mRNA out of the nucleus, even if the mRNA is encoded by an intron-less gene. Represses the splicing of MAPT/Tau exon 10. {ECO:0000269|PubMed:15009664, ECO:0000269|PubMed:19470458, ECO:0000269|PubMed:19574390, ECO:0000269|PubMed:21536736}.
Subcellular locationNucleus.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P26368
Gene Ontology
(Biological Process)
Complete annatation
mRNA 3'-end processing [GO:0031124];
mRNA export from nucleus [GO:0006406];
mRNA processing [GO:0006397];
mRNA splicing, via spliceosome [GO:0000398];
negative regulation of mRNA splicing, via spliceosome [GO:0048025];
positive regulation of protein targeting to mitochondrion [GO:1903955];
positive regulation of RNA splicing [GO:0033120];
regulation of mitophagy [GO:1903146];
RNA export from nucleus [GO:0006405];
termination of RNA polymerase II transcription [GO:0006369]
Gene Ontology
(Molecular Function)
Complete annatation
enzyme binding [GO:0019899];
nucleotide binding [GO:0000166];
poly(A RNA binding [GO:0044822];
poly-pyrimidine tract binding [GO:0008187];
pre-mRNA 3'-splice site binding [GO:0030628]
Gene Ontology
(Cellular Component)
Complete annatation
commitment complex [GO:0000243];
nuclear speck [GO:0016607];
nucleoplasm [GO:0005654];
nucleus [GO:0005634];
spliceosomal complex [GO:0005681];
U2AF [GO:0089701];
U2-type prespliceosome [GO:0071004]
Protein-protein interaction116466
Phylogenetic treeP26368
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD30.6688230599567480.04181362288206520.0859077312306675
AZA vs. DISU0.1474967832716850.5595603349335120.950206522099159
AZA vs. IL70.05681427617324130.7670534420686960.999311006273513
AZA vs. SAHA-0.8459609425578950.002952703937543540.0438081290891057
DISU vs. CD3-0.5342270860750790.1427233209343960.246354212729313
DISU vs. IL7-0.1002571190594420.6903007236166890.918641998995145
DISU vs. SAHA-0.9906368264844110.0008014073558175740.0177096924626491
DMSO vs. AZA0.02581019885244440.8772042203558841
DMSO vs. CD3-0.6540930247601980.0415708236213350.082186936726432
DMSO vs. DISU-0.1233770871778980.6126967641351720.939289650701039
DMSO vs. IL70.03832473511107770.8307859580292390.963051812112721
DMSO vs. SAHA-0.8769501956219990.001031649019496480.0182702495567938
HIV vs. Mock in Activation0.2556374092664670.6810772985821360.999983755607037
HIV vs. Mock in Latency-0.009732197367100750.952856764421250.999834320637052
IL7 vs. CD3-0.6067130423119260.05981467837026130.127037712706066
SAHA vs. CD3-1.537651780590622.86585654359905e-050.000159484704992754
SAHA vs. IL7-0.9047612826773230.0008204858318000550.0100716640297671
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) unknown
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.234365 0.0827515
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
0.995 0.98 0.978 0.884 0.972
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

not found

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1JMT X-ray 2.2Å B=85-112.
1O0P NMR - A=372-475.
1OPI NMR - A=372-475.
1U2F NMR - A=148-237.
2G4B X-ray 2.5Å A=148-336.
2HZC X-ray 1.4Å A=148-229.
2M0G NMR - B=372-475.
2U2F NMR - A=258-342.
2YH0 NMR - A=148-342.
2YH1 NMR - A=148-342.
3VAF X-ray 2.4Å A/B=148-336.
3VAG X-ray 2.1Å A/B=148-336.
3VAH X-ray 2.5Å A/B=148-336.
3VAI X-ray 2.2Å A/B=148-336.
3VAJ X-ray 1.9Å A/B=148-336.
3VAK X-ray 2.1Å A/B=148-336.
3VAL X-ray 2.5Å A/B/D/I=148-336.
3VAM X-ray 2.4Å A/B=148-336.
4FXW X-ray 2.2Å A/C=375-475.
4TU7 X-ray 2.0Å A/B=148-336.
4TU8 X-ray 1.9Å A/B=148-336.
4TU9 X-ray 1.9Å A/B=148-336.
5EV1 X-ray 2.0Å A=141-341.
5EV2 X-ray 1.8Å A=141-341.
5EV3 X-ray 1.5Å A=141-341.
5EV4 X-ray 1.5Å A=141-341.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Tat upregulates 23166591

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa03040 Spliceosome - Homo sapiens (human)